Advancement in medical treatment for gastrointestinal stromal tumors (GISTs): a ray of hope

被引：0

作者：

Singh, Harpreet ^{[1
]}

Mohanto, Sourav ^{[2
]}

Chopra, Hitesh ^{[3
]}

Chopra, Shivani ^{[4
]}

Mishra, Arun Kumar ^{[5
]}

Venkatachalam, T. ^{[6
]}

Bin Emran, Talha ^{[7
,8
]}

机构：

[1] IFTM Univ, Sch Pharmaceut Sci, Moradabad, India

[2] Yenepoya, Yenepoya Pharm Coll & Res Ctr, Dept Pharmaceut, Mangalore, India

[3] Chitkara Univ, Chitkara Coll Pharm, Ctr Res Impact & Outcome, Rajpura, India

[4] Saveetha Inst Med & Tech Sci, Saveetha Sch Engn, Dept Biosci, Chennai, India

[5] IFTM Univ, SOS Sch Pharm, Moradabad, India

[6] Tamil Nadu Dr MGR Med Univ, Dept Pharmaceut Chem, JKKMMRFs Annai JKK Sampoorani Ammal Collage Pharm, Namakkal, India

[7] Daffodil Int Univ, Fac Allied Hlth Sci, Dept Pharm, Dhaka, Bangladesh

[8] BGC Trust Univ Bangladesh, Dept Pharm, Chittagong, Bangladesh

来源：

ANNALS OF MEDICINE AND SURGERY | 2025年 / 87卷 / 03期

关键词：

gastrointestinal stromal tumors; immunotherapy; molecular alterations; non-coding RNAs; predictive biomarkers; IMATINIB; METHYLATION; DIAGNOSIS; ADJUVANT; THERAPY;

D O I：

10.1097/MS9.0000000000002843

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Gastrointestinal stromal tumors (GISTs) present unique diagnostic and therapeutic challenges. This review highlights advancements facilitated by molecularly targeted therapies like imatinib for advanced, metastatic, and high-risk GISTs, underscoring their neoadjuvant/adjuvant utility and the importance of multidisciplinary care. Emerging avenues, including immunotherapy, PI3K/mTOR/HSP90 inhibitors, are examined, reflecting the evolving treatment landscape. Furthermore, it explores distinct clinical considerations for GIST subtypes like spindle cell, epithelioid, mixed, and SDH-deficient tumors. Crucially, identifying predictive biomarkers (molecular alterations, non-coding RNAs, SLITRK3 expression, aberrant DNA methylation, radiomics) is emphasized for optimizing individualized regimens and improving outcomes. Overall, the review highlights the remarkable advances in GIST treatment while emphasizing the need for ongoing research into novel, molecularly tailored therapeutic strategies.

引用

页码：1383 / 1393

页数：11

共 98 条

[11]

[Anonymous], 2018, ClinicalTrials.gov

[12]

[Anonymous], 2023, Study Details | Phase 3 Study of DCC-2618 Vs Placebo in Advanced GIST Patients Who Have Been Treated with Prior Anticancer Therapies |

[13]

[Anonymous], 2015, ClinicalTrials.gov

[14]

[Anonymous], 2019, Study Details | Nivolumab with or without Ipilimumab in Treating Patients with Metastatic Sarcoma that Cannot Be Removed by Surgery |

[15]

[Anonymous], 2010, Study Details | A Phase I/II Study of Sunitinib Malate (SU011248) in Patients with Gastrointestinal Stromal Tumor (GIST)

[16]

[Anonymous], 2013, Study Details | Dovitinib for Imatinib/Sumitinib-failed Gastrointestinal Stromal Tumors (GIST): TKI258

[17]

[Anonymous], 2009, Study Details | Five Year Adjuvant Imatinib Mesylate (Gleevec) in Gastrointestinal Stromal Tumor (GIST) |

[18]

[Anonymous], 2019, Study Details | Efficacy and Safety of PD-0332991 in Advanced Gastrointestinal Stromal Tumors Refractory to Imatinib and Sunitinib

[19]

[Anonymous], 2017, Study Details | Regorafenib in Patients with Metastatic And/or Unresectable Gastrointestinal Stromal Tumor |

[20]

[Anonymous], 2015, Study Details | Depsipeptide (Romidepsin) in Treating Patients with Metastatic or Unresectable Soft Tissue Sarcoma |

← 1 2 3 4 5 6 7 8 9 10 →